Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
72.31
+2.18 (+3.11%)
Delayed Quote
Updated: 4:00 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Today 16:05 EST
From
Exelixis, Inc.
Via
Business Wire
Exelixis (EXEL) Q3 2026 Earnings Call Transcript
↗
October 30, 2026
Cabozantinib sales grew 11% year over year as zanzalintinib advances toward FDA decisions.
Via
The Motley Fool
Topics
Earnings
Retirement
What Exelixis (EXEL) Said on Its Q3 Earnings Call
↗
October 29, 2026
Exelixis (NASDAQ:EXEL) reported third-quarter 2026 revenue of approximately $659 million, supported by continued growth in its cabozantinib franchise and progress toward a potential launch of...
Via
MarketBeat
Topics
Earnings
Exelixis (NASDAQ:EXEL) Q3 Earnings Beat, Revenue In Line as Guidance Holds
↗
October 29, 2026
Via
Chartmill
Topics
Earnings
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital
↗
October 12, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup
↗
October 05, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals
↗
August 22, 2026
Via
Chartmill
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating
↗
August 06, 2026
Via
Chartmill
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
October 29, 2026
From
Exelixis, Inc.
Via
Business Wire
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
↗
October 26, 2026
Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.
Via
MarketBeat
Topics
Intellectual Property
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
↗
October 24, 2026
Exelixis will have to wait longer than expected to earn approval for a new drug. It's not the end of the world.
Via
The Motley Fool
Topics
Intellectual Property
Lawsuit
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered
↗
August 05, 2026
Via
Chartmill
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector
↗
July 01, 2026
Via
Chartmill
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health
↗
June 09, 2026
Via
Chartmill
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
↗
September 17, 2026
Exelixis (NASDAQ:EXEL) President and CEO Michael Morrissey said the company is focused on expanding its oncology franchises through internal development, selective business development and potential...
Via
MarketBeat
Topics
Artificial Intelligence
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
↗
September 15, 2026
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year....
Via
MarketBeat
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
↗
September 14, 2026
Exelixis (NASDAQ:EXEL) executives outlined a franchise-focused growth strategy centered on expanding CABOMETYX across renal cell carcinoma and neuroendocrine tumors while advancing zanzalintinib...
Via
MarketBeat
Topics
Artificial Intelligence
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
September 01, 2026
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
From
Exelixis, Inc.
Via
Business Wire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
August 16, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December.
Via
The Motley Fool
Topics
Earnings
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
August 12, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Exelixis Q2 Earnings Call Highlights
↗
August 05, 2026
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential...
Via
MarketBeat
Topics
Earnings
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From
Exelixis, Inc.
Via
Business Wire
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
↗
July 24, 2026
They are riding strong tailwinds that could lift them higher.
Via
The Motley Fool
Topics
Economy
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
From
Exelixis, Inc.
Via
Business Wire
3 Under-the-Radar Stocks to Buy and Hold
↗
July 10, 2026
Sometimes, little-known stocks are worth buying.
Via
The Motley Fool
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
From
Exelixis, Inc.
Via
Business Wire
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
